Expanding the Molecular Diversity of CIC-Rearranged Sarcomas With Novel and Very Rare Partners
Modern Pathology · 2023
DOI: 10.1016/j.modpat.2023.100103 ↗Kurz gefasst
Fachartikel in der Zeitschrift Modern Pathology, 2023. Verfasst von Konstantinos Linos und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, New York. Electronic address: linosk@mskcc.org. Hauptthemen laut MEDLINE: Sarcoma, Small Cell, Sarcoma, Ewing, Sarcoma. Die Arbeit wurde bisher 43-mal zitiert (Crossref) und nennt 53 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, Memorial Sloan Kettering Cancer Center.
Abstract (Originalsprache)
Capicua transcriptional repressor (CIC)-rearranged sarcoma represents a distinct pathologic entity and constitutes the second most prevalent category of undifferentiated round cell sarcomas (URCSs) after Ewing sarcoma. The 2 most common translocations are t(4;19) and t(10;19), resulting in CIC fusions with either DUX4 and DUX4L paralog, respectively; however, other rare variant fusions have also been reported. In this study, we expand the molecular spectrum of CIC-gene partners, reporting on 5 cases of URCSs showing CIC fusions with AXL, CITED1, SYK, and LEUTX by targeted RNA or DNA sequencing. There were 4 female patients and 1 male patient with a wide age range (12-70 years; median, 36 years). Four cases occurred in the deep soft tissues (lower extremity, 3; neck, 1) and 1 case in the central nervous system (midbrain/thalamus). All cases showed similar histologic findings within the spectrum of URCSs. Immunohistochemistry, showed variable positivity for ETV4 in 4 of the 4 cases and positive results for ERG in 3 of the 4 cases and for WT1 in 1 of the 4 cases. CD31 showed positivity in 2 of the 3 cases, including one coexpressing ERG. Unsupervised clustering of methylation profiles by T-distributed stochastic neighborhood embedding performed in 4 cases showed that all clustered tightly together and along the CIC sarcoma methylation class. RNA-sequencing data showed consistent upregulation of ETV1 and ETV4 mRNA in all cases examined, at similar levels to CIC::DUX4 URCSs. Our study expands the molecular diversity of CIC-rearranged URCSs to include novel and rare partners, providing morphologic, immunohistochemical, gene expression, and methylation evidence supporting their classification within the family of tumors harboring the more common DUX4/DUX4L partner genes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, New York. Electronic address: linosk@mskcc.org.
- Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.
- Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York.
- Department of Oncology, Memorial Sloan Kettering Cancer Center, New York, New York.
- Department of Pathology, Brigham & Women's Hospital, Harvard Medical School, Boston, Massachusetts.
Förderung
- NCI NIH HHS
- Memorial Sloan Kettering Cancer Center
Zitieren
APA
Linos, K., Dermawan, J. K., Bale, T., Rosenblum, M. K., Singer, S., Tap, W., Dickson, M. A., Hornick, J. L., & Antonescu, C. R. (2023). Expanding the Molecular Diversity of CIC-Rearranged Sarcomas With Novel and Very Rare Partners. Modern Pathology. https://doi.org/10.1016/j.modpat.2023.100103
Vancouver
Linos K, Dermawan JK, Bale T, Rosenblum MK, Singer S, Tap W, et al. Expanding the Molecular Diversity of CIC-Rearranged Sarcomas With Novel and Very Rare Partners. Modern Pathology. 2023. doi:10.1016/j.modpat.2023.100103
BibTeX
@article{Linos2023,
author = {Linos, Konstantinos and Dermawan, Josephine K and Bale, Tejus and Rosenblum, Marc K and Singer, Samuel and Tap, William and Dickson, Mark A and Hornick, Jason L and Antonescu, Cristina R},
title = {Expanding the Molecular Diversity of CIC-Rearranged Sarcomas With Novel and Very Rare Partners},
journal = {Modern Pathology},
year = {2023},
doi = {10.1016/j.modpat.2023.100103}
}
EUVIMED